Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
AssigneeThe General Hospital Corporation
InventorsDavid R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4′-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof.
Claims4
A compound, wherein the compound is
A pharmaceutical composition comprising a pharmaceutically acceptable carrier;
- and a compound, wherein the compound is
A method for amyloid imaging a subject suffering from an amyloidosis-associated pathological condition selected from Alzheimer's disease and senile dementia, comprising the step of:
- administering a compound, or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, to the subject;
- wherein the compound is
A method for treating a subject suffering from an amyloidosis-associated pathological condition selected from Alzeimer's disease and senile dementia, comprising the step of:
- administering a compound, or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier, to the subject;
- wherein the compound is
Dependencies are inferred from the claim text.